Trabectedin

(Yondelis®)

Trabectedin

Drug updated on 11/10/2023

Dosage FormInjection (intravenous; 1 mg)
Drug ClassAlkylating agents
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • For the treatment of patients with unresectable or metastatic liposarcoma or leiomyosarcoma who received a prior anthracycline-containing regimen.

Product Monograph / Prescribing Information

Document TitleYearSource
Yondelis (trabectedin) Prescribing Information.2020Janssen Products, LP, Horsham, PA

Systematic Reviews / Meta-Analyses